阿昔单抗与比伐卢定联合低分子肝素治疗非ST段抬高心肌梗死的疗效比较  

Comparison of the efficacy of abciximab and bivalirudin combined with low molecular weight heparin in the treatment of the patients with non ST segment elevation myocardial infarction

作　　者：胡玲[1] 

机构地区：[1]南阳市中心医院心血管外科,河南南阳473009

出　　处：《中国医院药学杂志》2014年第11期929-932,共4页Chinese Journal of Hospital Pharmacy

摘　　要：目的:对阿昔单抗与比伐卢定联合低分子肝素治疗非ST段抬高心肌梗死(NSTEMI)的疗效进行分析和比较。方法:选取80例NSTEMI作为研究对象,将其按照随机数字法分为观察组和对照组,每组各40例,2组患者均给予常规硝酸盐、β-受体阻滞剂、血管紧张素转化酶抑制剂等药物治疗。在此基础上,对照组患者给予比伐卢定治疗静脉滴注,同时给予低分子肝素皮下注射治疗;观察组患者给予阿昔单抗静脉滴注治疗。对2组的临床疗效、患者的心电图改善情况和治疗的安全性进行观察和分析。结果:经过治疗,2组的临床有效率分别为97.5%和67.5%,观察组的临床有效率显著高于对照组(P<0.05),且观察组患者中疗效为显效的比例显著高于对照组(P<0.05);2组患者的心电图改善总有效率分别为90%和62.5%,观察组的总有效率显著高于对照组(P<0.05),且观察组患者的心电图改善为显效的比例显著高于对照组(P<0.05);在治疗期内,观察组未见死亡病例,对照组患者死亡3例,2组均未见严重不良反应,2组患者的死亡率和不良反应发生情况的差异无显著性(P>0.05)。疗程结束后2组患者均未见血常规、凝血功能及肝功能等指标异常。结论:阿昔单抗治疗NSTEMI较应用比伐卢定联合低分子肝素治疗的疗效更好,对患者心功能的改善作用更强,且安全性较高,值得在临床上应用。OBJECTVE To analyze and compare the efficacy of abciximab and bivalirudin combined with low molecular weight heparin in the treatment of the patients with non ST segment elevation myocardial infarction （NSTEMI）. METHODS 80 patients with NSTEMI were selected as the research objects and randomly divided into the observation group and the control group. 40 cases were included in each group. The patients in the two groups were treated with the conventional drugs such as nitrates, beta blockers, angiotensin converting enzyme inhibitors. On this basis, the patients in the control group were treated with hivalirudin therapy by means of the intravenous drip combined with low molecular weight heparin by means of subcutane-ous injection while the patients in the observation group were treated with abciximab by intravenous infusion. The clinical cura- tive effects, therapeutic improvement on ECG and safety of the two groups were observed and analyzed. RESULTS After treat- ment, the clinical efficiency rate of the two groups were 97. 5% and 67. 5% and the clinical efficiency rate of the observation group was significantly higher than that of the control group （P〈0.05）. The ratio of the patients with marked clinical effects in the observation group was significantly higher than that in the control group （P〈0. 05） ; the total effective rate of ECG im- provement of the two groups were 90% and 62. 5% and the total effective rate of the observation group was significantly higher than that in control group （P〈0. 05）. The ratio of the patients with marked ECG improvements in the observation group was significantly higher than that in the control group （P〈0. 05） ; in the treatment period, no death cases were observed in the ob- servation group and 3 cases of death were observed in the control group. No serious adverse reactions were observed in the two groups. The differences of incidences mortality and adverse reactions were not significant （P^0. {）5）. After treatment, the two groups of patients sh

关 键 词：阿昔单抗 比伐卢定 低分子肝素 非ST段抬高心肌梗死 疗效观察 

分 类 号：R973.2[医药卫生—药品]